Novartis looks set to repurpose cancer drug in MS after tria...

Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.

Weekly roundup: More questions for Novartis in Zolgensma sca...

It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.

Fallout over Zolgensma data scandal continues for Novartis

Novartis axed Avexis execs ahead of Zolgensma scandal

The plot thickens at Novartis, which is becoming embroiled in a scandal over falsification of data related to its rare disease gene therapy Zolgensma.

Pharming buys rare disease drug from Novartis for $20m

Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.

Novartis' heart failure drug misses expanded use trial targe...

Novartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped would extend its use to a new group of patients with preserved ejection fraction.